A Randomized, Double-Blind, Placebo-Controlled, 52-Week Study of the Efficacy and Safety of Belimumab Administered Subcutaneously Plus Standard Care to Patients with Systemic Lupus Erythematosus (SLE)

被引：0
|
作者：
Stohl, William [1 ]
Schwarting, Andreas [2 ]
Okada, Masato [3 ]
Scheinberg, Morton [4 ]
Doria, Andrea [5 ]
Hammer, Anne [6 ]
Kleoudis, Christi [7 ]
Bass, Damon [8 ]
Groark, James [9 ]
Fox, Norma Lynn [10 ]
Roth, David [11 ]
Gordon, David [11 ]
机构：
[1] Univ So Calif, Keck Sch Med, Div Rheumatol, Los Angeles, CA 90033 USA
[2] ACURA Kliniken, Bad Kreuznach, Germany
[3] St Lukes Int Hosp, Immunorheumatol Ctr, Tokyo, Japan
[4] Rheumatol Hosp Abreu Sodre Pesquisa Clin, Sao Paulo, Brazil
[5] Univ Padua, Div Rheumatol, Padua, Italy
[6] GlaxoSmithKline, Res Triangle Pk, NC USA
[7] Parexel, Durham, NC USA
[8] GlaxoSmithKline, Immunoinflammat, King Of Prussia, PA USA
[9] GlaxoSmithKline, Philadelphia, NC USA
[10] GlaxoSmithKline, Washington, MD USA
[11] GlaxoSmithKline, Philadelphia, PA USA
来源：
ARTHRITIS & RHEUMATOLOGY | 2015年 / 67卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3218
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study
    Stohl, William
    Schwarting, Andreas
    Okada, Masato
    Scheinberg, Morton
    Doria, Andrea
    Hammer, Anne E.
    Kleoudis, Christi
    Groark, James
    Bass, Damon
    Fox, Norma Lynn
    Roth, David
    Gordon, David
    ARTHRITIS & RHEUMATOLOGY, 2017, 69 (05) : 1016 - 1027
  • [2] Year-5 Follow-up of Belimumab Safety (mortality and Malignancies) in Patients with Systemic Lupus Erythematosus (SLE) Who Completed a Phase 4, 52-week, Randomized, Double-blind Placebo-controlled Safety Study
    Sheikh, Saira
    Wei, James Cheng-Chung
    Tegzova, Dana
    Stohl, William
    de Toledo, Ricardo Acayaba
    Mucenic, Tamara
    Abello Banfi, Mauricio R.
    Maksimowicz-McKinnon, Kathleen
    Abud-Mendoza, Carlos
    Navarra, Sandra
    Garcia, Mercedes
    Garcia-De La Torre, Ignacio
    Fernandes, Sofia
    Harris, Julia H. N.
    Roy, Abhishek
    Olaiz, Jose Miyar
    Wilde, Paul
    Roth, David A.
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 2956 - 2958
  • [3] Sustained Efficacy and Safety of Iberdomide to Week 52 in Patients with Active Systemic Lupus Erythematosus (SLE) in a Phase 2, Randomized, Placebo-Controlled Study
    Merrill, Joan
    Werth, Victoria
    Furie, Richard
    van Vollenhoven, Ronald
    Majdan, Maria
    Weiswasser, Michael
    Korish, Shimon
    Liu, Zhaohui
    Schafer, Peter
    Delev, Nikolay
    ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 3059 - 3062
  • [4] EFFICACY AND SAFETY OF TABALUMAB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): RESULTS FROM 2 PHASE 3, 52-WEEK, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED TRIALS
    Isenberg, D.
    Merrill, J.
    Hoffman, R.
    Linnik, M.
    Morgan-Cox, M.
    Veenhuizen, M.
    Iikuni, N.
    Dickson, C.
    Silk, M.
    Wallace, D.
    Doerner, T.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 141 - 141
  • [5] ONSET AND DURABILITY OF EFFICACY OF BELIMUMAB ADMINISTERED SUBCUTANEOUSLY PLUS STANDARD OF CARE MEDICATIONS TO PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) IN A PHASE III TRIAL
    Doria, A.
    Stohl, W.
    Schwarting, A.
    Hammer, A.
    Fox, N. I.
    Groark, J.
    Bass, D.
    Pobiner, B.
    Edwards, L.
    Eastman, W.
    Gordon, D.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2016, 34 (04) : S13 - S13
  • [6] Bromocriptine in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled study
    Alvarez-Nemegyei, J
    Cobarrubias-Cobos, A
    Escalante-Triay, F
    Sosa-Munoz, J
    Miranda, JM
    Jara, LJ
    LUPUS, 1998, 7 (06) : 414 - 419
  • [7] Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study
    Isenberg, D. A.
    Petri, M.
    Kalunian, K.
    Tanaka, Y.
    Urowitz, M. B.
    Hoffman, R. W.
    Morgan-Cox, M.
    Iikuni, N.
    Silk, M.
    Wallace, D. J.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 (02) : 323 - 331
  • [8] Clinical and Laboratory Correlates of Response in a Phase 3 Clinical Trial of Belimumab or Placebo Administered Subcutaneously Plus Standard Care to Patients with Systemic Lupus Erythematosus (SLE)
    van Vollenhoven, Ronald F.
    Stohl, William
    Furie, Richard
    Fox, Norma Lynn
    Groark, James
    Bass, Damon
    Kurtinecz, Milena
    Pobiner, Bonnie
    Eastman, William
    Gonzalez-Rivera, Tania
    Gordon, David
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [9] A Phase II, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of Belimumab in Patients With Active Systemic Lupus Erythematosus
    Wallace, Daniel J.
    Stohl, William
    Furie, Richard A.
    Lisse, Jeffrey R.
    McKay, James D.
    Merrill, Joan T.
    Petri, Michelle A.
    Ginzler, Ellen M.
    Chatham, W. Winn
    McCune, W. Joseph
    Fernandez, Vivian
    Chevrier, Marc R.
    Zhong, Z. John
    Freimuth, William W.
    ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2009, 61 (09): : 1168 - 1178
  • [10] EFFICACY AND SAFETY OF TELITACICEPT, A NOVEL BLYS/APRIL DUAL INHIBITOR, IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED 52-WEEK STUDY
    Wang, L.
    Li, J.
    Xu, D.
    Fang, J.
    Van Vollenhoven, R.
    Zhang, F.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 90 - 91
12345